Bacillus calmette-guerin substrain danish 1331 live antigen
- Generic Name
- Bacillus calmette-guerin substrain danish 1331 live antigen
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 4CGF0IDN3W
- Background
BCG SSI has been used in trials studying Tuberculosis.
Heterologous Effects of BCG in Healthy UK Adults
Not Applicable
Completed
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 36
- Registration Number
- NCT02380508
- Locations
- 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom
A Clinical Challenge Study of BCG in Healthy Volunteers
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 52
- Registration Number
- NCT02088892
- Locations
- 🇬🇧
The Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom
🇬🇧Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath